15-48446795-C-T
Variant summary
Our verdict is Pathogenic. Variant got 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000138.5(FBN1):c.5699G>A(p.Cys1900Tyr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 11/18 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. C1900S) has been classified as Pathogenic.
Frequency
Consequence
NM_000138.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 19 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FBN1 | NM_000138.5 | c.5699G>A | p.Cys1900Tyr | missense_variant | 47/66 | ENST00000316623.10 | NP_000129.3 | |
FBN1 | NM_001406716.1 | c.5699G>A | p.Cys1900Tyr | missense_variant | 46/65 | NP_001393645.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FBN1 | ENST00000316623.10 | c.5699G>A | p.Cys1900Tyr | missense_variant | 47/66 | 1 | NM_000138.5 | ENSP00000325527.5 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Marfan syndrome Pathogenic:2
Pathogenic, no assertion criteria provided | clinical testing | Center for Medical Genetics Ghent, University of Ghent | Nov 07, 2017 | - - |
Pathogenic, criteria provided, single submitter | research | Centre of Medical Genetics, University of Antwerp | Mar 01, 2021 | PM2, PVS2, PP4 - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 14, 2014 | p.Cys1900Tyr (TGT>TAT): c.5699 G>A in exon 47 of the FBN1 gene (NM_000138.4)The C1900Y mutation in the FBN1 gene has been reported in association with Marfan syndrome (Baetens M et al., 2011; Arbustini E et al., 2005; Attanasio M et al., 2008). Attanasio et al. (2008) reported one individual who met the Ghent criteria for Marfan syndrome, whose features included: pectus carinatum, pes planus, positive wrist and thumb sign, dilation of the ascending aorta, MVP, ectopia lentis and striae. Arbustini et al. (2005) described two patients with C1900Y who met the Ghent criteria for Marfan syndrome. Patient one had aortic root dilation, MVP, ectopia lentis and skeletal findings. Patient two had dural ectasia, skin, eye and skeletal findings without major cardiac findings. C1900Y results in a non-conservative amino acid substitution of Cysteine at a position that is conserved across species. Other mutations affecting the same residue (C1900F, C1900S) and mutations affecting nearby residues (C1895R, C1895Y, G1903Y, G1903R, C1905R) have been reported in association with Marfan syndrome, further supporting the functional importance of this region of the protein. Furthermore, the C1900Y mutation was not observed inapproximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations.In summary, C1900Y in the FBN1 gene is interpreted as a disease-causing mutation. The variant is found in TAAD panel(s). - |
Marfan syndrome;C4707243:Familial thoracic aortic aneurysm and aortic dissection Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 13, 2023 | This sequence change replaces cysteine, which is neutral and slightly polar, with tyrosine, which is neutral and polar, at codon 1900 of the FBN1 protein (p.Cys1900Tyr). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Marfan syndrome (PMID: 16222657, 18435798, 21542060). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 200066). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FBN1 protein function with a positive predictive value of 95%. This variant affects a cysteine residue in the EGF-like, TGFBP or hybrid motif domains of FBN1. Cysteine residues are believed to be involved in intramolecular disulfide bridges and have been shown to be important for FBN1 protein structure (PMID: 16905551, 19349279). In addition, missense substitutions affecting cysteine residues within these domains are significantly overrepresented among patients with Marfan syndrome (PMID: 16571647, 17701892). This variant disrupts the p.Cys1900 amino acid residue in FBN1. Other variant(s) that disrupt this residue have been observed in individuals with FBN1-related conditions (PMID: 19293843, 19839986, 22772377), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at